The following abstracts represent Posters W1-W39 that were presented at IWWM-10 (NYC-2018) Poster Session. "ORAL" signifies a 10-minute oral presentation was given during the poster session.
Session Chairs: Ranjana Advani (USA) and Marvin Stone (USA)
W1: MYD88 p.(L265P) detection on cell-free DNA in plasma and cerebrospinal fluid L. Hiemcke-Jiwa, Netherlands
W2: Treatment of IgM-associated immunoglobulin light chain amyloidosis with Bendamustine-Rituximab R. Manwani, United Kingdom
W3: Mast Cell Density and Its Clinical Relevance in Waldenström's Macroglobulinemia R. Lemal, France
W4: Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia J. Paludo, USA
W5: Depth of Response in Waldenstrom Macroglobulinemia J. Paludo, USA
W6: Efficacy of zanubrutinib in the treatment of Bing Neel Syndrome J. Wong, Australia
W7: Updated Analysis of Half-Dose CHOP Combined with Rituximab as Primary Therapy for Symptomatic Waldenström Macroglobulinemia: Single Institutional Experience in Japan N. Sekiguchi, Japan
W8: Serum Transforming Growth Factor-Beta 1 (TGF-BETA 1) Levels predict survival and time to Treatment in Waldenstrom's macroglobulinemia (WM) M.C. Kyrtsonis, Greece
W10: Sequential analysis of TP53 variation using targeted Next Generation Sequencing (NGS) in patients with Waldenström Macroglobulinemia A Christian, United Kingdom
W11: A single centre case series of patients with Waldenström's Macroglobulinemia and Acquired von Willebrand Syndrome L.F. Gamble, United Kingdom
W12: Digital PCR is highly sensitive method for the detection of MYD88 L265P mutation in bone marrow trephine biopsies of lymphomas with plasmacytic/plasmacytoid differentiation E. Willenbacher, Austria
W13: Detection of MYD88 L265P mutation by digital PCR in peripheral blood samples from IgM monoclonal gammopathy patients E. Abella, Spain
W14: Natural history of IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia N. Tovar, Spain
W15: The EBMT/ECWM/IWMF consensus project on the role of autologous and allogeneic stem cell transplantation in Waldenstrom's Macroglobulinemia C. Kyriakou, United Kingdom
W16: Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstrom Macroglobulinemia reveals different patterns of clonal evolution D. Talaulikar, Australia
W17: Philadelphia chromosome positive acute lymphoblastic leukemia arising in Waldenstrom's macroglobulinemia J. Kothari, United Kingdom
W18: WhiMSICAL (Waldenstrom's Macroglobulinemia Study Involving Cart-wheeL): A Global WM Registry for the Patient's Voice I Tohidi-Esfahani, Australia
W21: Dual PAK4-NAMPT Inhibition Impacts Growth and Survival and Increases Sensitivity to DNA-Damaging Agents in Waldenstrom Macroglobulinemia M Fulciniti, USA
W22: Bleeding disorders associated with IgM paraproteinemia and response to treatment: Illustrative Case series from Waldenstrom Macroglobulinemia United Kingdom (WMUK) Forum R. Krishna, United Kingdom
W23 ORAL: Incidence and inheritance of hyperphosphorylated paratag-7 in patients with Waldenstrom's Macroglobulinemia from Sweden L. Brandefors, Sweden
W24: Real World Experience of Bendamustine in Waldenstrom's Macroglobulinaemia (WM): efficacy tempered by toxicity H. Richards, United Kingdom
W25: The Rory Morrison Registry (RMR) for Waldenstrom Macroglobulinemia: A successful doctor-patient collaboration for comprehensive data collection on all-WMer’s J. Bomsztyk, United Kingdom
W26: Novel phenotypically distinct small B cell lymphoma clones may be associated with IgM paraprotein associated peripheral neuropathy L. Chen, United Kingdom
W27: Waldenstrom Macroglobulinaemia: Patient characteristics and outcomes according to MYD88 status in a UK population MD. El-Sharkawi, United Kingdom
W28: IgM Smoldering Multiple Myeloma in a young patient over six years follow-up: case report of an extremely rare hematologic entity A Abbadessa, Italy
W29: Long Term follow-up of Waldenstrom Macroglobulinemia patients’ primary treated with Dexamethasone, Rituximab, and Cyclophosphamide: a single centre experience V. Del Fabro, Italy
W31: Waldenstrom's Macroglobulinemia in Young Patients: Disease Characteristics and Clinical Outcome in Patients aged less than 55 years I Defrancesco, Italy
W33: Progression risk-based classification of Asymptomatic Waldenström Macroglobulinemia: a large single-center study M. Bustoros, USA
W34: Discriminating between Waldenström's Macroglobulinemia and Marginal zone lymphoma using clinicopathological and molecular features K. Amaador, Netherlands
W36: TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinemia J. Gustine, USA
W37: Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenström Macroglobulinemia J. Gustine, USA
W39: BLIMP1 as a pro-survival gene in Waldenström's Macroglobulinemia E. Magnúsdóttir, Iceland